Equities

Royalty Pharma PLC

Royalty Pharma PLC

Actions
  • Price (EUR)24.40
  • Today's Change0.22 / 0.91%
  • Shares traded4.04k
  • 1 Year change-1.05%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 14:49 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,2342,4282,803
Total Receivables, Net373768
Total Inventory------
Prepaid expenses------
Other current assets, total3.80916.63
Total current assets1,2742,5552,878
Property, plant & equipment, net------
Goodwill, net------
Intangibles, net--05.67
Long term investments15,10114,22914,628
Note receivable - long term------
Other long term assets6.52304.15
Total assets16,38216,81317,516
LIABILITIES
Accounts payable------
Accrued expenses525458
Notes payable/short-term debt000
Current portion long-term debt/capital leases0998--
Other current liabilities, total95107108
Total current liabilities1611,167171
Total long term debt6,1356,1197,096
Total debt6,1357,1167,096
Deferred income tax------
Minority interest3,5583,8974,472
Other liabilities, total0.902.50--
Total liabilities9,85511,18511,739
SHAREHOLDERS EQUITY
Common stock0.110.110.11
Additional paid-in capital4,0113,6663,508
Retained earnings (accumulated deficit)2,5181,9652,255
Treasury stock - common(2.63)(2.81)(2.72)
Unrealized gain (loss)--016
Other equity, total0.000.000.00
Total equity6,5265,6285,777
Total liabilities & shareholders' equity16,38216,81317,516
Total common shares outstanding447443433
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.